João Bandarra

Title: João Bandarra: Innovator in Pharmaceutical Processes

Introduction

João Bandarra is a notable inventor based in Loures, Portugal. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for the manufacture of important compounds. With a total of 2 patents, his work has implications for both medical treatments and industrial applications.

Latest Patents

One of João Bandarra's latest patents is titled "Process for the manufacture of iohexol." This process involves alkylating 5-Acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide using 2(2-methoxy-ethoxy)-ethanol as a solvent in the presence of a base. The process also includes the optional isolation of crude iohexol from the reaction mixture. The preferred alkylating agent is 1-chloro-2,3 propanediol, while the base can be an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide. Another significant patent is for the "Process for the preparation of mometasone furoate." This invention provides a new method for preparing mometasone 17-furoate, a steroid derivative useful in treating inflammatory diseases, through direct esterification of the 17 hydroxyl group without prior protection of the free 11 hydroxy function.

Career Highlights

João Bandarra is currently associated with Hovione Inter Limited, a company known for its expertise in pharmaceutical manufacturing. His work at Hovione has allowed him to focus on innovative processes that enhance the efficiency and effectiveness of drug production.

Collaborations

Throughout his career, João has collaborated with notable colleagues such as William Heggie and José Galindro. These partnerships have contributed to the advancement of his research and the successful development of his patented processes.

Conclusion

João Bandarra stands out as an influential inventor in the pharmaceutical industry, with a focus on innovative processes that have the potential to improve medical treatments. His contributions through his patents reflect a commitment to advancing pharmaceutical science.